KBC Group NV Buys New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

KBC Group NV purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,593 shares of the company’s stock, valued at approximately $35,000.

A number of other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC lifted its holdings in Dianthus Therapeutics by 9.2% in the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after acquiring an additional 814 shares during the period. Barclays PLC grew its position in shares of Dianthus Therapeutics by 390.5% in the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after purchasing an additional 33,185 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter worth $556,000. Wellington Management Group LLP purchased a new stake in shares of Dianthus Therapeutics in the 3rd quarter valued at approximately $1,473,000. Finally, State Street Corp raised its position in Dianthus Therapeutics by 101.4% in the third quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after purchasing an additional 413,425 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Up 1.1 %

Shares of DNTH stock opened at $23.31 on Tuesday. Dianthus Therapeutics, Inc. has a fifty-two week low of $18.34 and a fifty-two week high of $33.77. The business has a fifty day simple moving average of $23.00 and a 200-day simple moving average of $25.75. The stock has a market cap of $689.91 million, a P/E ratio of -9.32 and a beta of 1.72.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on DNTH shares. TD Cowen started coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Finally, Oppenheimer increased their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $46.43.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.